Corcept Therapeutics Inc. vs. Johnson & Johnson
Johnson & Johnson (JNJ) comes out ahead, leading on 9 of 9 compared factors.
Size & Scale
| CORT | JNJ | |
|---|---|---|
| Market Cap | $12.13 billion | $628.65 billion |
| Revenue (TTM) | $741.17 million | $97.93 billion |
| Net Income (TTM) | $106.11 million | $21.04 billion |
JNJ leads on 3 of 3 size & scale factors.
Valuation
| CORT | JNJ | |
|---|---|---|
| P/E Ratio | 131.57 | 30.20 |
| Price / Book | 19.19 | 7.40 |
| Price / Sales | 16.36 | 6.42 |
JNJ leads on 3 of 3 valuation factors.
Profitability
| CORT | JNJ | |
|---|---|---|
| Net Margin | 14.32% | 21.48% |
| Return on Equity | 16.79% | 24.76% |
JNJ leads on 2 of 2 profitability factors.
Dividend
| CORT | JNJ | |
|---|---|---|
| Dividend Yield | — | 2.06% |
| Payout Ratio | — | 62.18 |
CORT and JNJ split the dividend factors evenly.
Risk & Sentiment
| CORT | JNJ | |
|---|---|---|
| Short Interest | 16.06% | 0.67% |
JNJ leads on 1 of 1 risk & sentiment factors.
Dig deeper: CORT overview, CORT financials, JNJ overview, JNJ financials.
Comparisons use delayed, cached fundamental data and cover only the factors shown. For informational purposes only — not investment advice.